BML-278

BML-278

• CAS Number: 120533-76-8
• UNSPSC Description: BML-278 is a SIRT1 activator (EC150: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts[1][2].
• Target Antigen: Histone Methyltransferase; Sirtuin
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/bml-278.html
• Purity: 98.49
• Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CCOC(C1=CN(C=C(C(OCC)=O)C1C2=CC=CC=C2)CC3=CC=CC=C3)=O
• Molecular Weight: 391.46
• References & Citations: [1]Adamkova K, et al. SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development. J Anim Sci Biotechnol. 2017 Nov 1;8:83.|[2]Mai A, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem. 2009 Sep 10;52(17):5496-504.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported